Market Report -- In Play (IDRA)
November 25, 2009 8:00 AM ET
Idera Pharma and Merck extend research collaboration for agonists of toll-like receptors as vaccine adjuvants Co announces that Merck (MRK) has extended its research collaboration with Idera for a fourth year. As part of the agreement, the two companies engaged in a two-year research and development collaboration to generate novel agonists targeting TLR7 and TLR8 and incorporating both Merck and Idera chemistry for use in vaccines in the licensed fields, with Merck having the right to extend the collaboration for two additional one-year periods.
Briefing.com is the leading Internet provider of live market analysis for U.S. Stock, U.S. Bond, and world FX market participants.
Read more In Play articles
Back to News Home
- MSN Money
- Search MSN Money
- Message Boards
- Site Status
For today's top Money video click here
E-mail this article
Print-friendly version
Discuss this article